Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group

Amongst other points, these updated clinical practice recommendations suggest zoledronic acid as the preferred bone-targeted agent for patients with newly diagnosed multiple myeloma, with or without multiple myeloma-related bone disease. Denosumab can also be considered.

Source:

The Lancet Oncology